{"schema_version":"secwatch.filing_event.v1","accession":"0001815776-25-000017","form_type":"8-K","ticker":"LENZ","cik":"0001815776","company_name":"LENZ Therapeutics, Inc.","filed_at":"2025-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.017344+00:00","generated_at":"2026-05-24T12:08:36.850863+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"LENZ Therapeutics reports FY2024 net loss $49.8M; LNZ100 PDUFA set for Aug 8, 2025","bullets":["FDA accepted NDA for LNZ100 (presbyopia); PDUFA target action date Aug 8, 2025; no advisory committee planned.","Cash, cash equivalents & marketable securities $209.1M; cash runway expected to post-launch positive operating cash flow.","FY2024 net loss $49.8M ($2.34/share) vs FY2023 net loss $70.0M ($35.71/share).","R&D expenses fell to $29.8M in FY2024 from $59.5M in FY2023 as Phase 3 CLARITY study concluded.","SG&A expenses rose to $28.8M in FY2024 from $12.9M in FY2023 due to pre-commercial buildout for potential LNZ100 launch."],"urls":{"canonical":"https://secwatch.observer/filing/0001815776-25-000017","json":"https://secwatch.observer/filing/0001815776-25-000017.json","markdown":"https://secwatch.observer/filing/0001815776-25-000017.md","text":"https://secwatch.observer/filing/0001815776-25-000017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815776/000181577625000017/0001815776-25-000017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815776/000181577625000017/lenz-20250319.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T12:08:36.850863+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}